Adipose tissue as a target of hIV-1 antiretroviral drugs. potential consequences on metabolic regulations

Current Pharmaceutical Design

Volumn 16, Issue 30, 2010, Pages 3352-3360

  Caron Debarle, Martine ^a,b   Boccara, Franck ^a,b,c   Lagathu, Claire ^a,b   Antoine, Bénédicte ^a,b   Cervera, Pascale ^a,b,c   Bastard, Jean Philippe ^a,b,c   Vigouroux, Corinne ^a,b,c   Capeau, Jacqueline ^a,b,c  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cardio metabolic risk; Inflammation; Insulin resistance; Lipoatrophy; Lipohypertrophy; Mitochondrial dysfunction; Nucleoside analogue reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METFORMIN; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PIOGLITAZONE; PRAVASTATIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TENOFOVIR; THYMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URIDINE; ZIDOVUDINE;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; AGING; ARTICLE; ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENTIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE METABOLISM; HEART INFARCTION; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPLASIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPOATROPHY; LIPOHYPERTROPHY; METABOLIC DISORDER; METABOLIC REGULATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBCUTANEOUS FAT; TISSUE DISTRIBUTION;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; ANTI-HIV AGENTS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; MITOCHONDRIA; OXIDATIVE STRESS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 78649822338     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563446     Document Type: Article

References (146)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
2. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; 4: 293-301.
3. Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
4. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A: D) study. J Infect Dis 2010; 201: 318-330.
5. Thiebaut R, El-Sadr WM, Friis-Moller N, et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005; 10: 811-823.
6. Crane HM, Grunfeld C, Harrington RD, Kitahata MM. Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med 2009; 10: 496-503.
7. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16: F1-8.
8. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18: 641-649.
9. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D: A: D) study. Diabetes Care 2008; 31: 1224-1229.
10. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45: 111-119.
11. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21: 1739-1745.
12. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19: 1375-1383.
13. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2: 812-822.
14. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329-1338.
15. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8: 617-626.
16. Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, Caron M. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006; 11: 25-34.
17. Viengchareun S, Caron M, Auclair M, et al. Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir Ther 2007; 12: 919-929.
18. Stankov MV, Lucke T, Das AM, Schmidt RE, Behrens GM. Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors. Antimicrob Agents Chemother 2010; 54: 280-287.
19. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18: 2127-2136.
20. Stankov MV, Schmidt RE, Behrens GM. Zidovudine impairs adipogenic differentiation through inhibition of clonal expansion. Antimicrob Agents Chemother 2008; 52: 2882-2889.
21. Lagathu C, Bastard JP, Auclair M, et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004; 9: 911-920.
22. Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005; 10: 207-213.
23. Lagathu C, Eustace B, Prot M, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12: 489-500.
24. Caron M, Auclair M, Vissian A, Vigouroux C, Capeau J. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther 2008; 13: 27-38.
25. Day BJ, Lewis W. Oxidative stress in NRTI-induced toxicity: evidence from clinical experience and experiments in vitro and in vivo. Cardiovasc Toxicol 2004; 4: 207-216.
26. Deveaud C, Beauvoit B, Hagry S, et al. Site specific alterations of adipose tissue mitochondria in 3'-azido-3'-deoxythymidine (AZT)- treated rats: an early stage in lipodystrophy? Biochem Pharmacol 2005; 70: 90-101.
27. Lagathu C, Kim M, Maachi M, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005; 87: 65-71.
28. Kosmiski LA, Miller HL, Klemm DJ. In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival. Antivir Ther 2006; 11: 187-195.
29. Pacenti M, Barzon L, Favaretto F, et al. Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS 2006; 20: 1691-1705.
30. Esposito V, Manente L, Perna A, et al. Role of NEDD8 in HIVassociated lipodystrophy. Differentiation 2009; 77: 148-153.
31. Stankov MV, Schmidt RE, Behrens GM. Combined effect of Creactive protein and stavudine on adipogenesis. Antivir Ther 2009; 14: 819-829.
32. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-20254.
33. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 1378-1388.
34. Kachko I, Maissel A, Mazor L, et al. Postreceptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate. Endocrinology 2009; 150: 2618-2626.
35. Djedaini M, Peraldi P, Drici MD, et al. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun 2009; 386: 96-100.
36. Grigem S, Fischer-Posovszky P, Debatin KM, Loizon E, Vidal H, Wabitsch M. The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes. Horm Metab Res 2005; 37: 602-609.
37. Carper MJ, Cade WT, Cam M, et al. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulinsensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2008; 294: E558-E567.
38. Ben-Romano R, Rudich A, Tirosh A, et al. Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta. Diabetologia 2004; 47: 1107-1117.
39. Mondal D, Larussa VF, Agrawal KC. Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases. AIDS Res Hum Retroviruses 2001; 17: 1569-1584.
40. Rudich A, Ben-Romano R, Etzion S, Bashan N. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 2005; 183: 75-88.
41. Ben-Romano R, Rudich A, Etzion S, et al. Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. Antivir Ther 2006; 11: 1051-1060.
42. Adler-Wailes DC, Guiney EL, Koo J, Yanovski JA. Effects of ritonavir on adipocyte gene expression: evidence for a stressrelated response. Obesity (Silver Spring) 2008; 16: 2379-2387.
43. Parker RA, Flint OP, Mulvey R, et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 2005; 67: 1909-1919.
44. Domingo P, Vidal F, Domingo JC, et al. Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005; 35: 771-780.
45. Kim RJ, Wilson CG, Wabitsch M, Lazar MA, Steppan CM. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring) 2006; 14: 994-1002.
46. Caron M, Auclair M, Donadille B, et al. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ 2007; 14: 1759-1767.
47. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19: 1807-1818.
48. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003; 17: 2437-2444.
49. Stankov MV, Schmidt RE, Behrens GM. Impact of stimulatory pathways on adipogenesis and HIV-therapy associated lipoatrophy. Exp Biol Med (Maywood) 2009; 234: 1484-1492.
50. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20: 1813-1821.
51. De Barros S, Zakaroff-Girard A, Lafontan M, Galitzky J, Bourlier V. Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9. J Pharmacol Exp Ther 2007; 320: 291-299.
52. Jones SP, Waitt C, Sutton R, Back DJ, Pirmohamed M. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS 2008; 22: 1293-1298.
53. Vernochet C, Azoulay S, Duval D, et al. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem 2005; 280: 2238-2243.
54. Caron M, Vigouroux C, Bastard JP, Capeau J. Antiretroviral- Related Adipocyte Dysfunction and Lipodystrophy in HIV-Infected Patients: Alteration of the PPARgamma-Dependent Pathways. PPAR Res 2009; 2009: 507141.
55. Cotter EJ, Mallon PW, Doran PP. Is PPARgamma a Prospective Player in HIV-1-Associated Bone Disease? PPAR Res 2009; 2009: 421376.
56. Dowell P, Lane MD. C/EBPalpha reverses the anti-adipogenic effects of the HIV protease inhibitor nelfinavir. Biochem Biophys Res Commun 2005; 327: 571-574.
57. Soliman MM, El-Senosi YA, Salem MM, Abdel Hamid OM, Kazuhiro K. Role of protease inhibitors and acylation stimulating protein in the adipogenesis in 3T3-L1 cells. J Vet Sci 2009; 10: 197-201.
58. Kovsan J, Ben-Romano R, Souza SC, Greenberg AS, Rudich A. Regulation of adipocyte lipolysis by degradation of the perilipin protein: nelfinavir enhances lysosome-mediated perilipin proteolysis. J Biol Chem 2007; 282: 21704-21711.
59. Kovsan J, Osnis A, Maissel A, et al. Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy. Am J Physiol Endocrinol Metab 2009; 296: E315-E322.
60. Coffinier C, Hudon SE, Farber EA, et al. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci U S A 2007; 104: 13432-13437.
61. Coffinier C, Hudon SE, Lee R, et al. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J Biol Chem 2008; 283: 9797-9804.
62. Yan Q, Hruz PW. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 2005; 40: 398-403.
63. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviralnaive HIV-infected patients. Clin Infect Dis 2006; 42: 273-280.
64. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711-718.
65. Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E. High molecular weight form of adiponectin in antiretroviral drug-induced dyslipidemia in HIV-infected Japanese individuals based on in vivo and in vitro analyses. Intern Med 2009; 48: 1799-1875.
66. Boyd M, Reiss P. The long-term consequences of antiretroviral therapy: a review. J HIV Ther 2006; 11: 26-35.
67. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-1118.
68. El Hadri K, Glorian M, Monsempes C, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem 2004; 279: 15130-15141.
69. Caron M, Auclair M, Kornprobst M, Lagathu C, Capeau J. Nevirapine did not alter cell differentiation, lipid metabolism, insulin response and survival in cultured adipocytes. Antivir Ther 2004; 9: L27.
70. Rodriguez de la Concepcion ML, Domingo JC, Domingo P, Giralt M, Villarroya F. Uncoupling protein 1 gene expression implicates brown adipocytes in highly active antiretroviral therapy-associated lipomatosis. AIDS 2004; 18: 959-960.
71. Boccara F, Caron M, Auclair M, Capeau J. Irbesartan, an angiotensin II receptor I blocker, prevents the adverse effects of HIV antiretrovirals on adipocyte functions. Antivir Ther 2006; 11: L7.
72. Villarroya F, Domingo P, Giralt M. Drug-induced lipotoxicity: Lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim Biophys Acta 2010; 1801(3): 392-399.
73. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-1031.
74. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004; 9: 555-564.
75. Domingo P, Matias-Guiu X, Pujol RM, Francia E, Lagarda E, Sambeat MA, Vazquez G. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999; 13: 2261-2267.
76. Sievers M, Walker UA, Sevastianova K, et al. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitorassociated lipoatrophy. J Infect Dis 2009; 200: 252-262.
77. McComsey GA, Libutti DE, O'Riordan M, et al. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther 2008; 13: 715-722.
78. Kratz M, Purnell JQ, Breen PA, et al. Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy. J Clin Endocrinol Metab 2008; 93: 959-966.
79. Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286: E261-E271.
80. Hammond E, Nolan D. Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapyassociated lipodystrophy. Curr Opin HIV AIDS 2007; 2: 274-281.
81. Cherry CL, Lal L, Thompson KA, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2005; 38: 263-267.
82. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191: 1686-1696.
83. Boothby M, McGee KC, Tomlinson JW, et al. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther 2009; 14: 1089-1100.
84. Kim MJ, Leclercq P, Lanoy E, et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIVinfected patients: the ANRS EP29 Lipostop Study. Antivir Ther 2007; 12: 1273-1283.
85. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAARTassociated lipodystrophy. Antivir Ther 2006; 11: 729-740.
86. Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 2007; 21: 2183-2190.
87. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292: E1666-E1673.
88. Riddle TM, Schildmeyer NM, Phan C, Fichtenbaum CJ, Hui DY. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res 2002; 43: 1458-1463.
89. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001; 7: 1327-1331.
90. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-2982.
91. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviralnaive cohort. HIV Med 2005; 6: 114-121.
92. Hellerstein MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 76: 559-565.
93. Woods MN, Wanke CA, Ling PR, et al. Metabolic syndrome and serum fatty acid patterns in serum phospholipids in hypertriglyceridemic persons with human immunodeficiency virus. Am J Clin Nutr 2009; 89: 1180-1187.
94. Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIVInfected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr 2007; 45: 66-71.
95. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect 2005; 50: 331-337.
96. Capeau J, Magré J, Caron M, Lagathu C, Bastard JP, Vigouroux C. Genetic and acquired lipodystrophies: from fat redistribution to insulin resistance and aging. Future Lipidol. 2006; 1: 593-604.
97. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003; 14: 398-403.
98. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
99. Torriani M, Thomas BJ, Barlow RB, Librizzi J, Dolan S, Grinspoon S. Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution. J Appl Physiol 2006; 100: 609-614.
100. Gan SK, Samaras K, Thompson CH, et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002; 51: 3163-3169.
101. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIVinfected men under antiretroviral therapy. AIDS 2003; 17: 1503-1511.
102. Lihn AS, Richelsen B, Pedersen SB, et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003; 285: E1072-E1080.
103. Semple RK, Sleigh A, Murgatroyd PR, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009; 119: 315-322.
104. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002; 51: 1143-1147.
105. Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007; 45: 286-297.
106. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350: 1220-1234.
107. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726-735.
108. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140-1142.
109. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-671.
110. Haugaard SB, Andersen O, Volund A, et al. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clin Endocrinol (Oxf) 2005; 62: 354-361.
111. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145: 397-406.
112. Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765-3773.
113. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009; 53: 577-584.
114. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110: 1507-1512.
115. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
116. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003; 4: 43-55.
117. Schling P, Mallow H, Trindl A, Loffler G. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord 1999; 23: 336-341.
118. Boustany CM, Bharadwaj K, Daugherty A, et al. Activation of the systemic and adipose renin-angiotensin system in rats with dietinduced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004; 287: R943-R949.
119. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue reninangiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807-825.
120. Hegele RA, Leff T. Unbuckling lipodystrophy from insulin resistance and hypertension. J Clin Invest 2004; 114: 163-165.
121. Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21: 1377-1382.
122. Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19: 953-960.
123. Boccara F, Auclair M, Cohen A, et al. HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther 2010; 15.
124. Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92: 386-395.
125. Tsai YS, Kim HJ, Takahashi N, et al. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J Clin Invest 2004; 114: 240-249.
126. Takemori K, Gao YJ, Ding L, et al. Elevated blood pressure in transgenic lipoatrophic mice and altered vascular function. Hypertension 2007; 49: 365-372.
127. Xu ZG, Lanting L, Vaziri ND, et al. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation 2005; 111: 1962-1969.
128. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
129. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-270.
130. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavirbased substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 22-28.
131. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029-1036.
132. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 207-215.
133. Tebas P, Zhang J, Yarasheski K, et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 2007; 45: 193-200.
134. Tebas P, Zhang J, Hafner R, et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 2009; 63: 998-1005.
135. Slama L, Lanoy E, Valantin MA, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebocontrolled trial (ANRS 113). Antivir Ther 2008; 13: 67-76.
136. Sutinen J. The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients. PPAR Res 2009; 2009: 373524.
137. Mallon PW, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIVinfected men--a randomized, placebo-controlled study. AIDS 2006; 20: 1003-1010.
138. Sutinen J, Walker UA, Sevastianova K, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007; 12: 97-105.
139. McComsey GA, O'Riordan M, Setzer B, et al. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr 2008; 62: 1031-1037.
140. Roubenoff R, Schmitz H, Bairos L, et al. Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 2002; 34: 390-393.
141. Driscoll SD, Meininger GE, Ljungquist K, et al. Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2004; 89: 2171-2178.
142. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86: 504-510.
143. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010; 53(3): 311-322.
144. Barbaro G, Klatt EC. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr Pharm Des 2003; 9(18): 1475-1481.
145. Barbaro G. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr Pharm Des 2007; 13(21): 2208-2213.
146. Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, Scott JD. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 2006; 12(9): 1075-1090.